This is a promotional email for UK healthcare professionals only, sent by Otsuka Pharmaceuticals (UK) Ltd.
Prescribing information for Abilify Maintena® (aripiprazole) prolonged-release suspension for injection can be found via the link in this email. Abilify Maintena® is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. |
 |
Dear {{accTitle}} {{accLname}},
We are delighted to invited you to an educational meeting with promotional content organised and funded by Otsuka Pharmaceuticals (UK) Ltd. Join our chair Dr Benson Benjamin as he introduces presentations from Professor David Taylor, Dr Sofia Pappa and Mr John Donoghue which explore the treatment challenges in schizophrenia.
The following talks followed by Q&A will feature:
- Professor David Taylor - Understanding long-acting injectable antipsychotic medication
- Dr Sofia Pappa – Neurodysfunction in psychosis: Relevance to better patient outcomes and implications for personalised treatments
- Mr John Donoghue - Schizophrenia and the physical health challenge: mortality, physical health, and antipsychotics
|
 |
 |
AGENDA |
|
|
| |
 |
09:45-10:15 |
Arrival and registration |
10:15-10:30 |
Chair's opening and welcome, Dr Benson Benjamin |
10:30-11:30 |
Professor David Taylor - Understanding long-acting injectable antipsychotic medication |
11:30-11:50 |
Q&A session |
11:50-12:35 |
Lunch |
12:35-13:35 |
Dr Sofia Pappa - Neurodysfunction in psychosis: Relevance to better patient outcomes and implications for personalised treatments |
13:35-13:55 |
Q&A session |
13:55-14:15 |
Coffee break |
14:15-15:15 |
Mr John Donoghue - Schizophrenia and the physical health challenge: Mortality, physical health, and antipsychotics |
15:15-15:35 |
Q&A session |
15:35-16:00 |
Chair’s closing remarks |
| |
|
|
 |
|
|
MEET THE CHAIR & SPEAKERS |
 |
 |
Dr. Benson Benjamin
Dr Benjamin is a Consultant Psychiatrist working in Liaison psychiatry in King George Hospital under the North East London NHS Foundation Trust (NELFT) Directorate. He has a special interest in Neuropsychiatry and provides Neuropsychiatry Input to the Acute Medical Trust at BHR Hospitals University Trust. He has specialised in General Adult and Old Age psychiatry, having trained at the Barts and London Training scheme for Psychiatry. |
|
|
 |
Professor David Taylor
Professor Taylor is Director of Pharmacy and Pathology at the South London and Maudsley NHS Foundation Trust and Professor of Psychopharmacology at King’s College, London. In 2021, he became the only pharmacist ever to be elected an Honorary Fellow of the Royal College of Psychiatrists. He is also Editor-in-Chief of the journal Therapeutic Advances in Psychopharmacology, has been the lead author of the Maudsley Prescribing Guidelines since 1993 and has written approximately 400 clinical papers which are cited widely. |
|
|
 |
Dr Sofia Pappa
In addition to working as a Consultant Psychiatrist and Mood and Psychosis Research Lead at West London NHS Trust, Dr Pappa is also an Honorary Senior Lecturer, Department of Brain Sciences, at Imperial College London, Speciality Lead in Mental Health for the National Institute for Health Research (NIHR) and an Associate Clinical Professor in Psychiatry for RUSM Medical School (Florida, US). She has dual training in Neurology and Psychiatry and her interests focus on Neuropsychopharmacology (particularly novel treatments) and Neuropsychiatry. Dr Pappa has acted as Principal Investigator for several clinical trials and has published in high impact journals. |
|
|
 |
Mr John Donoghue
John is a former mental health pharmacist. He has worked in the NHS in senior roles both clinically and in NHS management and was the manager of a Department of Health project in community mental health which won a national award. He is a past chairman of the UK Psychiatric Pharmacy Group and a founding member of the College of Mental Health Pharmacy. In 2012 he was made a fellow of the College in recognition of his contribution to mental healthcare. He has written widely on mental health issues and has over 80 peer-reviewed publications including book chapters and commentaries and presented at many international symposia. He has also created and delivered many educational packages related to the treatment of severe mental illness which have been used both in the UK and internationally. |
|
|
|
Kind regards,
{{userName}}
{{User.Title}}
{{User.Phone}}{{userEmailAddress}}
|
|
For information on how Otsuka UK process your personal data, and how you can exercise your rights in connection with this, please visit: www.otsuka.co.uk/HCPPRIVACY/Notice
Prescribing information for Abilify Maintena® GB can be found here
This email is intended for you only, please do not forward. Should you consider that other healthcare professional colleagues may benefit from attending this event, please let me know.
To unsubscribe from receiving promotional emails from Otsuka
please click here |
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Otsuka Pharmaceuticals (UK) Ltd. by email to OPUKSafety@otsuka.co.uk
or by calling 0808 168 6726
|
|
 |